A 52-year-old man with newly diagnosed multiple myeloma (ISS stage II) is being initiated on chemotherapy. He has normal renal function (eGFR 85 mL/min/1.73m²), no prior malignancy, and is otherwise fit. The oncologist plans to use melphalan as part of the induction regimen. Before starting melphalan, what is the most appropriate immediate next step?

Explanation

## Management Before Melphalan Initiation in Multiple Myeloma ### Why Allopurinol/Febuxostat Prophylaxis is the Most Appropriate Next Step **Key Point:** Before initiating melphalan-based chemotherapy in multiple myeloma, prophylactic urate-lowering therapy (allopurinol or febuxostat) is the most appropriate immediate next step to prevent **tumor lysis syndrome (TLS)** and hyperuricemia-related acute kidney injury. Multiple myeloma carries a significant tumor burden, and alkylating agents like melphalan cause rapid cell lysis, releasing large quantities of intracellular purines → uric acid. This can precipitate: - Uric acid nephropathy and acute kidney injury - Hyperkalemia, hyperphosphatemia, hypocalcemia (classic TLS electrolyte disturbances) - Cardiac arrhythmias in severe cases **High-Yield (Harrison's Principles of Internal Medicine):** Allopurinol (xanthine oxidase inhibitor) or febuxostat is recommended prophylactically before initiating cytotoxic chemotherapy in hematologic malignancies with significant tumor burden, including multiple myeloma. This is a standard pre-treatment step per NCCP and oncology guidelines. ### Why Option C (Mesna + Aggressive Hydration) is Incorrect **Critical Distinction:** Mesna (2-mercaptoethanesulfonate sodium) is a **uroprotective agent specifically indicated for cyclophosphamide and ifosfamide**, which generate the toxic metabolite **acrolein** responsible for hemorrhagic cystitis. Melphalan does **NOT** produce acrolein and therefore mesna is **NOT indicated** for melphalan-based regimens. | Agent | Acrolein Production | Mesna Indicated? | |---|---|---| | Cyclophosphamide | Yes | Yes | | Ifosfamide | Yes | Yes | | Melphalan | No | **No** | | Busulfan | No | No | While general hydration is always prudent, the specific combination of "mesna + aggressive hydration" as the *most appropriate immediate next step* is incorrect for melphalan. ### Why Other Options Are Incorrect | Option | Reasoning | |---|---| | A) Bone marrow biopsy | Already performed at diagnosis; not needed before treatment initiation | | B) PFTs/Echocardiography | Melphalan is not significantly cardiotoxic or pulmonary-toxic at standard induction doses; not the immediate priority | | C) Mesna + hydration | Mesna is NOT indicated for melphalan (no acrolein); this is a classic distractor | **Clinical Pearl (KD Tripathi – Essentials of Medical Pharmacology):** Mesna is co-administered with oxazaphosphorine alkylating agents (cyclophosphamide, ifosfamide) only. For other alkylating agents such as melphalan, chlorambucil, and busulfan, mesna has no role. TLS prophylaxis with allopurinol or febuxostat is the standard pre-chemotherapy measure in high-burden hematologic malignancies. **Warning:** Do not confuse the class-wide recommendation for hydration with the specific indication for mesna — they are not interchangeable, and mesna is not a substitute for allopurinol in TLS prevention.